Gamma Pharmaceuticals Gamma Pharmaceuticals http://chinasecurities.com/ir/GammaPharmaceuticals en-US 09 Mar 2010 14:37:00 GMT 10 Feb 2012 13:21:48 GMT [Press Release] Gamma Pharmaceuticals "Goes for the Jugular," message_4979 09 Mar 2010 14:37:00 GMT http://chinasecurities.com/ir/GammaPharmaceuticals/messages/4979

LAS VEGAS, March 9, 2010 (GLOBE NEWSWIRE) -- Gamma Pharmaceuticals, Inc. (Pink Sheets:GMPM - News) ("Gamma" or the "Company") announced the formation of a joint venture company with Jugular, Inc. ("Jugular"), replacing the brand licensing agreement in place between Gamma and Jugular since 2007. The new company, Gamma Jugular, LLC ("Gamma Jugular") is closely integrated with Gamma's existing corporate infrastructure and distribution channels, and currently has three product lines and six SKUs with plans for expansion. Under the terms of the joint venture, Gamma will consolidate Gamma Jugular's performance into Gamma's financials.

Peter Cunningham, Gamma's Chief Executive Officer, commented on the initiative, "Forming Gamma Jugular is important to the Company in two significant ways. First, we improve corporate control by integrating Gamma's infrastructure with Jugular, Inc. on our exclusive product range. Second, we eliminated a substantial debt obligation payable to Jugular per our Licensing Agreement from 2007. We believe this will provide management with additional flexibility in the future." Mr. Cunningham continued, "We have worked for two years developing our Jugular product line of energy products and high performance vitamins and nutriceuticals. The leading edge products we have developed achieved an 85% 'willingness to purchase' after the first try. Today, we are embarking on a national and global expansion, details of which we will release in the weeks ahead. We expect great things from the Gamma Jugular, 'Go for the Jugular' campaign."

On March 3rd 2010, Gamma announced that it has entered into a multi-year agreement with one of North America's leading wholesale distribution organizations to distribute the full line of Gamma products, which at full distribution equates to an annualized value of approximately $48.0 million. The Company will utilize a portion of the distribution arrangement to accelerate the rollout of the Gamma Jugular product range.

About Gamma Pharmaceuticals Inc.

Gamma Pharmaceuticals, Inc. (www.gammapharma.com) is a marketing and product formulation company selling its own branded products through wholesalers and direct to retailers, both in the U.S. and internationally. Gamma's core focus is the marketing and sale of vitamins and nutriceuticals, OTC pharmaceutical products and personal care products in the United States and Greater China. Branded nutritional supplements are sold under the trademarks Brilliant Choice(TM) children's nutritional supplements featuring the call to action "Mom you've made a brilliant choice for your children's nutrition;" SAVVY(TM) adult nutritional supplements featuring the call to action, "Be SAVVY Stay Healthy;" and, Jugular Energy Products(TM) and high performance supplements featuring the call to action, "Go for the Jugular(TM)." Gamma's customer focus is on selling products in the Lifestyle of Health & Sustainability ("LOHAS") marketplace and in the Energy Supplement Market. A series of innovative marketing programs supports Gamma's product sales and retail partners.

At present Gamma manufactures in North America, and distributes in the United States and China. Gamma's products utilize proprietary "Gel Delivery Technology(R)", to create innovative gel product forms, designed to give consumers a more pleasant experience. Gel Delivery Technology(R) characteristics include rapid absorption, convenience and taste great. Market categories Gamma targets are growing as rapidly as 60% per year. Gamma has developed formulas and strategies for Metabolic Syndrome and Diabetes Type II, Stress Reduction, Cognition, Well being, Menopause Symptoms and Personal Care Products. Gamma also develops and manufactures house brands for major retailers.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this Press Release regarding any impact the quotation of the Company's stock has on the Pink Sheets or the lack thereof on the OTCBB, and any other effects of the above are forward-looking statements. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

]]> [Press Release] Gamma Pharmaceuticals Announces Multi-Year Distribution Agreement message_4877 03 Mar 2010 13:30:00 GMT http://chinasecurities.com/ir/GammaPharmaceuticals/messages/4877

LAS VEGAS, NV--(Marketwire - 03/03/10) - Gamma Pharmaceuticals, Inc. (Pinksheets:GMPM - News): Gamma Pharmaceuticals, Inc. ("Gamma" or the "Company") announced that it has entered into a multi-year agreement (the "Agreement") with one of North America's leading wholesale distribution organizations to distribute the full line of Gamma products. The Agreement, which is evergreen in duration, provides for minimum monthly volume purchases of Gamma products at agreed upon pricing per SKU. The contracted terms cover the sale of 40,000 cases per month of Gamma's branded products, which at full distribution equates to an annualized value of approximately $48.0 million. Gamma's new distribution partner is one of the largest wholesale distributors of branded consumer products in North America, and is credited with the enormous commercial success of many leading consumer brands.

Peter Cunningham, Gamma's Chief Executive Officer, commented on the agreement, "We are extremely pleased to have successfully contracted with such an accomplished distributor. The distributor and its retail network share Gamma's view that our products have great commercial appeal. This guarantee arrangement takes Gamma from the pre-revenue, pre-EBITDA company it has been over the past two years to a company with approximately $48 million in minimum annualized revenues, and enables Gamma's management and shareholders to look forward with more certainty in anticipating our growth and profitability." Mr. Cunningham added, "Gamma now has in place a distribution platform that truly complements the Company's product portfolio. Gamma can now successfully extend its commercial reach to more effectively attract additional retail accounts that will drive revenues in the US market for years to come."

About Gamma Pharmaceuticals, Inc.

Gamma Pharmaceuticals, Inc. (www.gammapharma.com) is a marketing and product formulation company selling its own branded products through wholesalers and direct to retailers, both in the US and internationally. Gamma's core focus is the marketing and sale of vitamins and nutriceuticals, OTC pharmaceutical products and personal care products in the United States and Greater China. Branded nutritional supplements are sold under the trademarks Brilliant Choice™ children's nutritional supplements featuring the call to action "Mom you've made a brilliant choice for your children's nutrition;" SAVVY™ adult nutritional supplements featuring the call to action, "Be SAVVY Stay Healthy;" and, Jugular Energy Products™ and high performance supplements featuring the call to action, "Go for the Jugular™." Gamma's customer focus is on selling products in the Lifestyle of Health & Sustainability ("LOHAS") marketplace and in the Energy Supplement Market. A series of innovative marketing programs supports Gamma's product sales and retail partners.

At present Gamma manufactures in North America, and distributes in the United States and China. Gamma's products utilize proprietary "Gel Delivery Technology®," to create innovative gel product forms; that are designed to give consumers a more pleasant experience. Gel Delivery Technology® characteristics include rapid absorption, convenience and taste great. Market categories Gamma targets are growing as rapidly as 60% per year. Gamma has developed formulas and strategies for Metabolic Syndrome and Diabetes Type II, Stress Reduction, Cognition, Well being, Menopause Symptoms, and Personal Care Products. Gamma also develops and manufactures house brands for major retailers. At this time, Gamma has a total of 36 SKUs and holds licenses for 9 SKUs in China.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this Press Release regarding any impact the quotation of the Company's stock has on the Pink Sheets or the lack thereof on the OTCBB, and any other effects of the above are forward-looking statements. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

]]> [Press Release] Gamma Pharmaceuticals "Gets Fighting Fit" -- Forms Joint Venture message_4809 01 Mar 2010 12:30:00 GMT http://chinasecurities.com/ir/GammaPharmaceuticals/messages/4809

LAS VEGAS, NV--(Marketwire - 03/01/10) - Gamma Pharmaceuticals, Inc. (Pinksheets:GMPM - News): Gamma Pharmaceuticals, Inc. ("Gamma" or the "Company") announced the formation of a Joint Venture Company with Boxing World Heavyweight Champion Evander Holyfield. Mr. Holyfield is the only 4-time Boxing World Heavyweight Champion and in unaided focus groups is identified as one of the world's most recognized athletes. The joint venture, branded "Holyfield Choice," is formulating and marketing an innovative line of vitamins and nutritional products utilizing Mr. Holyfield's expertise in nutrition and physical training and Gamma's formulation and marketing knowhow. Holyfield Choice is closely integrated with Gamma's existing corporate infrastructure and distribution channels, and currently has four product lines and seven SKUs, with plans for expansion. Under the terms of the venture, Gamma will consolidate the joint venture's performance into Gamma's financials.

Evander Holyfield expressed great enthusiasm for his new venture with Gamma saying, "For several years I have searched for a partner to help me commercialize products that I know will work because I use the formulations and I live the program. Holyfield Choice represents the real Evander Holyfield and my personal expertise and passion for fitness -- at 47 years old I am more fit and energetic today than I was a decade ago. Gamma is the perfect partner for me and together we can make the world fighting fit."

Peter Cunningham, Gamma's Chief Executive Officer, commented on the initiative, "We believe the potential of the Holyfield's Choice brand is global and virtually limitless. Evander's truly remarkable fitness and stamina, especially at his age, is regarded with both wonder and admiration, and we believe consumers want to participate in his coveted 'fountain of youth.' Working closely with Evander, Gamma has specially formulated and dosed a complete line of supplements, vitamins and energy boosters that can form an important part of a health and fitness regimen designed to try to achieve the exceptional results that Evander 'The Real Deal' Holyfield has enjoyed for years."

Cunningham continued, "We're very excited and pleased to have this terrific opportunity with Evander come together. Both Gamma and the Holyfield organization have been working diligently refining our product formulation and taking the necessary steps to quickly roll out products and establish Holyfield Choice as a preferred consumer product. We have been in advance marketing discussions with the wholesale distribution channel and leading retailers, and the response has been remarkable. In addition, Evander will soon be launching the 'Holyfield Challenge,' a national fitness and health program aimed at school-age and college-age students that will be rolled out to secondary schools and colleges around the country. Holyfield Choice fitness, nutrition and supplement products will be a key element of this youth-oriented program. With our multi-channel, multi-product roll-out of the Holyfield Choice line now organized and beginning implementation, we eagerly anticipate an exciting future."

About Evander Holyfield

Evander Holyfield is a professional boxer from the United States and is the only 4-time World Heavyweight Champion earning him the nickname "The Real Deal." He is one of the most recognized athletes in the world. Outside of boxing, he has appeared in numerous television shows and movies including a 5th place finish on ABC's Dancing with the Stars in 2005. He is President of the Holyfield Foundation, created to help disadvantaged young people become healthy, successful and productive adults. The Holyfield Foundation strives to strengthen the lives of youth and their families by establishing and funding programs dedicated to their athletic, academic and spiritual development.

About Gamma Pharmaceuticals Inc

Gamma Pharmaceuticals, Inc., (www.gammapharma.com) is a marketing and product formulation company selling its own branded products through wholesalers and direct to retailers, both in the US and internationally. Gamma's core focus is the marketing and sale of vitamins and nutriceuticals, OTC pharmaceutical products and personal care products in the United States and Greater China. Branded nutritional supplements are sold under the trademarks Brilliant Choice™ children's nutritional supplements featuring the call to action "Mom you've made a brilliant choice for you children's nutrition;" SAVVY™ adult nutritional supplements featuring the call to action, "Be SAVVY Stay Healthy;" and, Jugular Energy Products™ and high performance supplements featuring the call to action, "Go for the Jugular™." Gamma's customer focus is on selling products in the Lifestyle of Health & Sustainability ("LOHAS") marketplace and in the Energy Supplement Market. A series of innovative marketing programs supports Gamma's product sales and retail partners.

At present Gamma manufactures in North America, and distributes in the United States and China. Gamma's products utilize proprietary "Gel Delivery Technology®," to create innovative gel product forms; that give consumers a more pleasant experience. Gel Delivery Technology® characteristics include rapid absorption, convenience and taste great. Market categories Gamma targets are growing as rapidly as 60% per year. Gamma has developed formulas and strategies for Metabolic Syndrome and Diabetes Type II, Stress Reduction, Cognition, Well being, Menopause Symptoms and Personal Care Products. Gamma also develops and manufactures house brands for major retailers. At this time, Gamma has a total of 36 SKU's and holds licenses for 9 SKUs in China.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this Press Release regarding any impact the quotation of the Company's stock has on the Pink Sheets or the lack thereof on the OTCBB, and any other effects of the above are forward-looking statements. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact:


 
Contact:
Gamma Pharmaceuticals Inc
Joe Cunningham
(jcunningham@gammapharma.com)
Direct:  (651) 204 2048
Office:  (702) 989 5262

]]> [Press Release] Gamma Pharmaceuticals CEO Peter Cunningham Releases Letter to Shareholders message_4782 25 Feb 2010 14:30:00 GMT http://chinasecurities.com/ir/GammaPharmaceuticals/messages/4782

LAS VEGAS, NV--(Marketwire - 02/25/10) - Gamma Pharmaceuticals, Inc. (Pinksheets:GMPM - News), a marketing and product formulation company selling its own branded products through wholesalers and direct to retailers, both in the US and internationally, today released a letter to shareholders from Peter Cunningham, Chief Executive Officer, providing investors with important announcements and Management's vision for the company for the remainder of 2010 and beyond.

Dear Shareholders:

It is my pleasure to write to you today to bring you details of multiple, concurrent corporate initiatives we are unveiling, which are designed to significantly expand Gamma's global market share and sales revenue in the vitamin, nutritional supplement and consumer healthcare market and, accordingly, the value to you, our shareholders. The difficult economic environment of the past two years delayed several of these initiatives, but also prompted Gamma Management to focus resources and position our products for maximum impact. It is our intent in the weeks and months ahead to provide our current investors regular updates as we execute on these initiatives.

As many of you know, during the past two years Gamma suffered set-backs which delayed our ability to execute the original business plan for the Company. Unfortunately, when our main funding provider defaulted on a substantial obligation to the Company, at the on-set of the global credit crisis, it forced Management to modify certain commercial arrangements and to renegotiate our purchase order and factoring credit facilities; ultimately effecting the execution of our initial strategy and impacting our timeline. However, Management used this period to establish multiple joint ventures, new distribution arrangements, new product formulations and product lines, and expanded marketing relationships that we believe should propel Gamma into an exciting new chapter of success.

In addition, while our customers and manufacturing partners have stood by the Company, Management adjusted its business model to be more effective in this new economy. We have reinforced relationships with our customers (both distributors and retailers), financing sources and manufacturers so that Gamma can focus on its core strengths of marketing and product formulation, creating significant new opportunities and reducing cost of goods by approximately 33%. In parallel, we have addressed the financial opportunities available to the Company. We believe all these initiatives should accelerate our growth and drive substantial revenue gains for years to come.

Importantly, we have entered into a long-term, minimum purchase contract with a leading U.S. distribution partner to market and distribute Gamma products, with contractual minimum set to achieve annualized sales of approximately $48 million. This crucial initiative transforms Gamma from the pre-revenue, pre-EBITDA Company it has been over the past two years into a company with substantial minimum annual revenues, which enables us to look forward with more certainty in anticipating our growth and profitability. Management views this minimum threshold as a strong base upon which to build a comprehensive offering of product lines and brands and to exploit opportunities with enormous potential. As of this writing, our order book contains millions of dollars in purchase orders and a robust order pipeline.

Next week we will announce a global product development and marketing joint venture with a world-famous athletic personality. Gamma is the controlling owner of a global joint venture that will formulate, market and distribute a specialty line of vitamins, nutritional supplements and health related products branded by a world-famous athlete who is revered for his exceptional fitness and stamina. Our initial strategic plan utilizes Gamma Gel Delivery Technology® for four product lines appealing to fitness-minded individuals including serious competitors and athletes. Our contract distributors have expressed high interest in a comprehensive roll-out of this branded product line alongside other Gamma brands, which we will target tens of thousands of retail outlets. We are actively in discussion on additional opportunities to exploit Gamma's expertise in product formulation and marketing, and we intend to opportunistically add business units or joint ventures as our market profile develops.

We have streamlined our balance sheet and reorganized our businesses using Gamma Pharmaceuticals as a holding company for numerous health and nutritional initiatives. Our distribution contracts and support provided by our contract manufacturers, supply chain and retailers have enabled Gamma to organize marketing and formulation initiatives and to reorganize certain debt obligations. We have reorganized a debt obligation with the Jugular™ license into a joint venture, enabling Gamma to eliminate substantial debt while not affecting Gamma's revenue or profitability. Gamma will continue as a product formulation and marketing company, thereby keeping our fixed costs low and focusing our resources on our highest value-added activities. Management believes this lean, focused approach is critical to maximizing shareholder value.

Our U.S. and global market positions are strong and improving and commanding the attention of retailers and end users alike. We is approached for media, promotion and public relations program launches at prices that are significantly less expensive than even one year ago. We are ready to launch our NBA, NHL, MLB and WNBA arena programs, Gamma Women Forum Series, sampling programs, point of sale and sweepstake programs at the retail level and now we have the distribution partners to keep our products moving through the retail channel. In today's economic environment, we anticipate costs savings on all corporate programs and will selectively seek additional opportunities. Recently, we secured trademark protection in China, and we are on track to expand our business in Southeast Asia including Hong Kong and China.

We have retained a leading middle-market investment bank and national law firm, significantly enhancing our financial, legal and administrative resources. During the past several months, Management has worked closely with its investment bankers and lawyers to finalize the initiatives discussed above. Our advisors have enabled us to more effectively negotiate, structure and execute more sophisticated transactions to drive our strategic initiatives. Further, given the rapidly evolving circumstances of the Company, our investment bankers are actively advising and assisting Gamma in identifying and considering various potential strategic and financial opportunities, including other potential joint ventures, acquisitions and capital raises.

To be certain, challenges remain, as in all businesses. Management has been extremely disappointed in the performance of our equity over the past 18 months, but is committed to driving shareholder value and to making every reasonable effort to ensure that the public has a full understanding of the tremendous opportunities at hand and those that will develop in the future. We believe this is a truly exciting time in Gamma's history.

I would like to close by thanking you for your confidence, patience and commitment to Gamma Pharmaceuticals. Our team has worked diligently to position our Company for future growth and profitability. I know of no other small company that has been able to marshal the resources that Gamma has at this time to enable us to make a substantial push into the market place and indelibly stamp our branded products on the consumer landscape. You can look forward to more frequent communication and we invite you to please contact us at our corporate headquarters should you have any questions or concerns or issues with what I have discussed here today.

I wish you a very successful 2010 and I hope that Gamma can be one stock you brag about owning.

Warmest regards,

/s/ Peter Cunningham

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this Press Release regarding any impact the quotation of the Company's stock has on the Pink Sheets or the lack thereof on the OTCBB, and any other effects of the above are forward-looking statements. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact:


 
Contact:
Gamma Pharmaceuticals, Inc.
Joe Cunningham
jcunningham@gammapharma.com
Office: (702) 989 5262
Direct: (651) 204 2048

]]> [Press Release] Gamma Pharmaceuticals Signs Distribution Agreement for $1.03 Million message_4516 21 Jan 2010 14:49:00 GMT http://chinasecurities.com/ir/GammaPharmaceuticals/messages/4516 LAS VEGAS, NV--(Marketwire - 01/21/10) - Gamma Pharmaceuticals Inc. (Pinksheets:GMPM - News) announced today that the Company has signed a Distribution Agreement for Gamma's branded product ranges. Under the Distribution Agreement, Gamma's monthly sales will ramp-up to $3.4 million. The first monthly purchase order has been accepted with a value of $1.03 million. The Agreement marks a significant milestone for Gamma, as it provides a key piece in the Company's North American Distribution plan. Gamma offers the industry's most distinctive blend of brands, product forms, marketing programs and market message all focused on moving products through large and profitable sales channels. The order received includes the Company's proprietary GELIbites�, GELIthins� and GELIcreams�. Peter Cunningham, Gamma CEO, commented, "We are very excited to have contracted with such a capable partner and are working diligently to piece together a distribution network that will drive high volume, high value sale for years to come. We feel that 2010 will be a game changer for Gamma in every respect as we deliver on our potential and drive shareholder value. We have a deep sales pipeline that we will fill in the weeks and months ahead."

About Gamma Pharmaceuticals Inc.

Gamma Pharmaceuticals Inc., (www.gammapharma.com) is a marketing and product formulation company selling its own branded products through wholesalers and direct to retailers, both in the US and internationally. Gamma's core focus is the marketing and sale of vitamins and nutriceuticals, OTC pharmaceutical products and personal care products in Greater China and the United States. Branded nutritional supplements are sold under the trademarks Brilliant Choice™ children's nutritional supplements featuring the call to action "Mom you've made a brilliant choice for you children's nutrition;" SAVVY™ adult nutritional supplements featuring the call to action, "Be SAVVY Stay Healthy;" and, Jugular Energy Products™ and high performance supplements featuring the call to action, "Go for the Jugular™." Gamma's customer focus is on selling products in the Lifestyle of Health & Sustainability ("LOHAS") marketplace and in the Energy Supplement Market. A series of innovative marketing programs supports Gamma's product sales and retail partners.

At present Gamma manufactures in North America, and distributes in the United States and China. Gamma's products utilize proprietary "Gel Delivery Technology�", to create innovative gel product forms; that give consumers a more pleasant experience. Gel Delivery Technology� characteristics include rapid absorption, convenience and taste great. Market categories Gamma targets are growing as rapidly as 60% per year. Gamma has developed formulas and strategies for Metabolic Syndrome and Diabetes Type II, Stress Reduction, Cognition, Well being, Menopause Symptoms, and Personal Care Products. Gamma also develops and manufactures house brands for major retailers. At this time, Gamma has a total of 36 SKUs and holds licenses for 9 SKUs in China.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this Press Release regarding any impact the quotation of the Company's stock has on the Pink Sheets or the lack thereof on the OTCBB, and any other effects of the above are forward-looking statements. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact:


 
Contact:
Gamma Pharmaceuticals Inc.
Joe Cunningham
(jcunningham@gammapharma.com)
Office:  (702) 989 5262
Direct:  (651) 204 2048
]]> [Press Release] Gamma Pharmaceuticals Secures Registered Trademark Protection in China message_3751 29 Oct 2009 12:30:00 GMT http://chinasecurities.com/ir/GammaPharmaceuticals/messages/3751 LAS VEGAS, NV and BEIJING--(Marketwire - 10/29/09) - Gamma Pharmaceuticals Inc. (the "Company") (Pinksheets:GMPM - News) announced it has successfully completed the registration of six of the Company's Brand Trademarks with The State Trademark Bureau of China. This important milestone is the conclusion of a two-year registration process and will provide Gamma with exclusivity of use and trademark protection on its commercial products in China.

Mr. Hao Zhang, Gamma's Chief Marketing Officer and China Representative, stated, "We are pleased to have the proper protection for our brands and recourse should there be any infringement. The Chinese nutritional supplement market is growing rapidly and we need to have the correct legal protections as we push our brand identity."

Gamma has a wholly owned subsidiary in Hong Kong and a Representative office in Beijing to facilitate its Asian business. Gamma's three founders have substantial business experience in Asia, having lived and worked there for nearly two decades. Gamma's management views the rapidly growing Chinese market as a key growth driver for the Company and have budgeted approximately $13 million in revenues for 2010 from the region. Gamma's intellectual property assets total nearly $6 million on the Company's balance sheet. Management's extensive Intellectual Property Management Program is designed to both protect these important assets and to grow their value.

About Gamma Pharmaceuticals Inc

Gamma Pharmaceuticals Inc., (www.gammapharma.com) is a marketing and product formulation company selling its own branded products through wholesalers and direct to retailers, both in the US and internationally. Gamma's core focus is the marketing and sale of vitamins and nutriceuticals, OTC pharmaceutical products and personal care products in Greater China and the United States. Branded nutritional supplements are sold under the trademarks Brilliant Choice(TM) children's nutritional supplements featuring the call to action, "Mom, you've made a brilliant choice for your children's nutrition"; SAVVY(TM) adult nutritional supplements featuring the call to action, "Be SAVVY Stay Healthy"; and Jugular Energy Products(TM) and high performance supplements featuring the call to action, "Go for the Jugular(TM)." Gamma's customer focus is on selling products in the Lifestyle of Health & Sustainability ("LOHAS") marketplace and in the Energy Supplement Market. A series of innovative marketing programs support Gamma's product sales and retail partners.

At present, Gamma manufactures in North America, and distributes in the United States and China. Gamma's products utilize proprietary "Gel Delivery Technology�" to create innovative gel product forms that give consumers a more pleasant experience. Gel Delivery Technology� characteristics include rapid absorption, convenience and superior taste. Market categories Gamma targets are growing as rapidly as 60% per year. Gamma has developed formulas and strategies for Metabolic Syndrome and Diabetes Type II, Stress Reduction, Cognition, Well being, Menopause Symptoms, and Personal Care Products. Gamma also develops and manufactures house brands for major retailers. At this time, Gamma has a total of 36 SKU's and holds licenses for 9 SKUs in China.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this Press Release regarding any impact the quotation of the Company's stock has on the Pink Sheets or the lack thereof on the OTCBB, and any other effects of the above are forward-looking statements. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact:


 
Contact:
Gamma Pharmaceuticals Inc
Joe Cunningham
(jcunningham@gammapharma.com)
Office:  (702) 989 5262
Direct:  (651) 204 2048
]]> [Press Release] Gamma Pharmaceuticals Announces Agreement With J&A Lazier Racing LLC message_3723 28 Oct 2009 12:30:00 GMT http://chinasecurities.com/ir/GammaPharmaceuticals/messages/3723 LAS VEGAS, NV--(Marketwire - 10/28/09) - Gamma Pharmaceuticals Inc. (the "Company") (Pinksheets:GMPM - News) announced it has signed a Product Brokerage Agreement with J&A Lazier Racing LLC of California. Mr. Lazier, an accomplished Indy Car Driver, will benefit from Gamma's Professional Grade vitamin supplements, nutritional and energy products to ensure peak athletic performance during the demanding Indy Car season. Gamma will make the products developed for the Indy Car race conditions available to consumers worldwide through Gamma's global distribution platform.

Peter Cunningham, Gamma's CEO, stated, "We are thrilled to be in business with such an elite global athlete and personality. Gamma will be Mr. Lazier's off-track pit crew. The objective is to keep Mr. Lazier in peak performance condition for the Indy Car season."

The Product Brokerage Agreement supports Gamma's entry into the world of Indy Car Racing. Indy Car Racing is the premier motor sport in the US with a substantial domestic and global following. The sport fits Gamma's global identity and up-market brand profile. The Indianapolis 500 is the largest single day sporting event in the world, attracting nearly 150 million television viewers and approximately 500,000 spectators. Gamma has built a full promotional and marketing program designed to attract motor sports fans to Gamma's branded products.

About Gamma Pharmaceuticals Inc

Gamma Pharmaceuticals Inc. (www.gammapharma.com) is a marketing and product formulation company selling its own branded products through wholesalers and direct to retailers, both in the US and internationally. Gamma's core focus is the marketing and sale of vitamins and nutriceuticals, OTC pharmaceutical products and personal care products in Greater China and the United States. Branded nutritional supplements are sold under the trademarks Brilliant Choice(TM) children's nutritional supplements featuring the call to action, "Mom, you've made a brilliant choice for you children's nutrition"; SAVVY(TM) adult nutritional supplements featuring the call to action, "Be SAVVY Stay Healthy"; and, Jugular Energy Products(TM) and high performance supplements featuring the call to action, "Go for the Jugular(TM)." Gamma's customer focus is on selling products in the Lifestyle of Health & Sustainability ("LOHAS") marketplace and in the Energy Supplement Market. A series of innovative marketing programs supports Gamma's product sales and retail partners.

At present Gamma manufactures in North America, and distributes in the United States and China. Gamma's products utilize proprietary "Gel Delivery Technology�," to create innovative gel product forms that give consumers a more pleasant experience. Gel Delivery Technology� characteristics include rapid absorption, convenience and taste great. Market categories Gamma targets are growing as rapidly as 60% per year. Gamma has developed formulas and strategies for Metabolic Syndrome and Diabetes Type II, Stress Reduction, Cognition, Well being, Menopause Symptoms, and Personal Care Products. Gamma also develops and manufactures house brands for major retailers. At this time, Gamma has a total of 36 SKU's and holds licenses for 9 SKUs in China.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this Press Release regarding any impact the quotation of the Company's stock has on the Pink Sheets or the lack thereof on the OTCBB, and any other effects of the above are forward-looking statements. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact:


 
Contact:
Gamma Pharmaceuticals Inc
Joe Cunningham
(jcunningham@gammapharma.com)
Office:  (702) 989 5262
Direct:  (651) 204 2048
]]> [Press Release] Gamma Pharmaceuticals Secures Funding for Order Fulfillment message_3600 13 Oct 2009 14:22:00 GMT http://chinasecurities.com/ir/GammaPharmaceuticals/messages/3600 LAS VEGAS, NV--(Marketwire - 10/13/09) - Gamma Pharmaceuticals Inc. (the "Company") (Pinksheets:GMPM - News) announced the Company has signed an Agreement for Purchase Order Financing and an Account Purchase (Factoring) facility. Combined, the financing package enables Gamma to amplify its manufacturing and retail resources in support of increased demand for the company's products and its substantial purchase order pipeline. Gamma already has in place marketing programs to support sales of the Company's own branded products nationwide. Joseph Cunningham, Gamma's CFO, commented, "We have found a great group to work with and have designed a financing solution that will compress our days outstanding and provide the financial resources to ramp-up our revenue profile." Last week, Gamma announced the signing of an Agreement-in-Principal (the "Agreement") with four-time World Heavyweight Champion, Evander Holyfield. The Agreement outlines a number of commercial opportunities including the development of the "Holyfield Theory" nutritional supplements and training programs as well as cross promotions and marketing support programs for Gamma's own branded products.

About Gamma Pharmaceuticals Inc

Gamma Pharmaceuticals Inc., (www.gammapharma.com) is a marketing and product formulation company selling its own branded products through wholesalers and direct to retailers, both in the US and internationally. Gamma's core focus is the marketing and sale of vitamins and nutriceuticals, OTC pharmaceutical products and personal care products in Greater China and the United States. Branded nutritional supplements are sold under the trademarks Brilliant Choice(TM) children's nutritional supplements featuring the call to action "Mom you've made a brilliant choice for you children's nutrition"; SAVVY(TM) adult nutritional supplements featuring the call to action, "Be SAVVY Stay Healthy"; and, Jugular Energy Products(TM) and high performance supplements featuring the call to action, "Go for the Jugular(TM)." Gamma's customer focus is on selling products in the Lifestyle of Health & Sustainability ("LOHAS") marketplace and in the Energy Supplement Market. A series of innovative marketing programs supports Gamma's product sales and retail partners.

At present Gamma manufactures in North America, and distributes in the United States and China. Gamma's products utilize proprietary "Gel Delivery Technology�," to create innovative gel product forms that give consumers a more pleasant experience. Gel Delivery Technology� characteristics include rapid absorption, convenience and taste great. Market categories Gamma targets are growing as rapidly as 60% per year. Gamma has developed formulas and strategies for Metabolic Syndrome and Diabetes Type II, Stress Reduction, Cognition, Well being, Menopause Symptoms, and Personal Care Products. Gamma also develops and manufactures house brands for major retailers. At this time, Gamma has a total of 36 SKU's and holds licenses for 9 SKUs in China.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this Press Release regarding any impact the quotation of the Company's stock has on the Pink Sheets or the lack thereof on the OTCBB, and any other effects of the above are forward-looking statements. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact:


 
Contact:
Gamma Pharmaceuticals Inc
Joe Cunningham
(jcunningham@gammapharma.com)
Office:  (702) 989 5262
Direct:  (651) 204 2048
]]> [Press Release] Gamma Pharmaceuticals Announces Agreement With Evander Holyfield message_3532 06 Oct 2009 13:55:00 GMT http://chinasecurities.com/ir/GammaPharmaceuticals/messages/3532 Las Vegas, NV--(Marketwire - 10/06/09) - Gamma Pharmaceuticals Inc. (the "Company")(Pinksheets:GMPM - News) announced the Company has signed an Agreement-in-Principal (the "Agreement") with four-time World Heavyweight Champion Evander Holyfield. The Agreement, first made public by Mr. Holyfield at a press conference on September 25, 2009 announcing Holyfield's health and green environmental initiatives, outlines a number of commercial opportunities including the development of the "Holyfield Theory" nutritional supplements and training programs as well as cross promotions and personal appearances with Gamma's own branded products. Gamma will assist Holyfield in the final product definition and formulation and have worldwide marketing and distribution rights. Evander Holyfield is one of the most recognized athletes in the world today. At 46, he is seeking to unify the world heavyweight division. Holyfield's next fight is set for November 8, 2009 in Seoul, South Korea. His training techniques and nutritional program have kept Holyfield in peak physical condition and has made him the envy of his peers. Holyfield with Gamma will define and commercialize his unique brand in the form of vitamins and nutritional supplements and workout programs. The products will be available worldwide through Gamma's global distribution platform.

Peter Cunningham, Gamma's CEO, stated, "We are thrilled to be in business with such an elite global athlete and personality. He truly transcends demographic groups, cultures and boarders and fits our philosophy and company ethos perfectly. He is the "Real Deal" and we aim to make a significant impact with his brand in our marketplace, it's a real knock out for Gamma."

Mr. Holyfield commented, "Gamma came with the right set of ideas and platform to enable me to make a meaningful contribution by commercializing my nutritional philosophy and training ideas and distributing them to the widest market available. I've gained immeasurable knowledge on health and nutrition through my many years of training and I'm really excited to have Gamma in my corner as we bring the products to market."

About Evander Holyfield

Evander Holyfield is a professional boxer from the United States and is the only 4-time World Heavyweight Champion earning him the nickname "The Real Deal". He is one of the most recognized athletes in the world. Outside of boxing, he has appeared in numerous Television shows and movies including a 5th place finish in 2005 on ABC's Dancing with the Stars. He is the President of the Holyfield Foundation, created to help disadvantaged young people become healthy, successful and productive adults. The Holyfield Foundation strives to strengthen the lives of youth and their families by establishing and funding programs dedicated to their athletic, academic and spiritual development.

About Gamma Pharmaceuticals Inc

Gamma Pharmaceuticals Inc. (www.gammapharma.com) is a marketing and product formulation company selling its own branded products through wholesalers and direct to retailers, both in the US and internationally. Gamma's core focus is the marketing and sale of vitamins and nutriceuticals, OTC pharmaceutical products and personal care products in Greater China and the United States. Branded nutritional supplements are sold under the trademarks Brilliant Choice(TM) children's nutritional supplements featuring the call to action "Mom you've made a brilliant choice for you children's nutrition;" SAVVY(TM) adult nutritional supplements featuring the call to action, "Be SAVVY Stay Healthhy;" and, Jugular Energy Products(TM) and high performance supplements featuring the call to action, "Go for the Jugular(TM)." Gamma's customer focus is on selling products in the Lifestyle of Health & Sustainability ("LOHAS") marketplace and in the Energy Supplement Market. A series of innovative marketing programs supports Gamma's product sales and retail partners.

At present Gamma manufactures in North America, and distributes in the United States and China. Gamma's products utilize proprietary "Gel Delivery Technology�", to create innovative gel product forms; that give consumers a more pleasant experience. Gel Delivery Technology� characteristics include rapid absorption, convenience and taste great. Market categories Gamma targets are growing as rapidly as 60% per year. Gamma has developed formulas and strategies for Metabolic Syndrome and Diabetes Type II, Stress Reduction, Cognition, Well being, Menopause Symptoms, and Personal Care Products. Gamma also develops and manufactures house brands for major retailers. At this time, Gamma has a total of 36 SKU's and holds licenses for 9 SKUs in China.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this Press Release regarding any impact the quotation of the Company's stock has on the Pink Sheets or the lack thereof on the OTCBB, and any other effects of the above are forward-looking statements. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact:


 
Contact:
Gamma Pharmaceuticals Inc
Joe Cunningham
jcunningham@gammapharma.com
Office:  (702) 989 5262
Direct:  (651) 204 2048
]]> [Press Release] Gamma Pharmaceuticals reach Agreement for Retail Market Coverage message_2506 23 Jun 2009 06:00:00 GMT http://chinasecurities.com/ir/GammaPharmaceuticals/messages/2506 LAS VEGAS, NV -- (Marketwire) -- 06/23/09 -- Gamma Pharmaceuticals Inc. (OTCBB: GMPM) announces an agreement with 360 Distribution, a major distributor in Texas. Gamma estimates a retail market value of approximately $750K in the first year. Gamma has established a very effective network of distributor resources and direct to retail systems throughout key markets in USA and China. 360 Distributors is another important link in Gamma's expanding distribution universe. Gamma's CEO, Peter Cunningham, commented, "We are pleased to team up with a high quality distributor like 360 Distributors that can provide direct distribution support for Gamma's retail promotions and market penetration. Retail chains are supportive of Gamma's aggressive promotion program for the territory and are taking product immediately."

Mr. Cunningham continued, "Major retailers' acceptance of Gamma's brands and promotion programs make the distributors confident to push the brands very hard in the marketplace."

Gamma Pharmaceuticals Inc. is a marketing and product formulation company. We have created, registered, and branded innovative product lines including Nutritional Supplements, Personal Care Products and Over-The-Counter (OTC) pharmaceuticals. At present Gamma manufactures in North America, and distributes in the United States and China. Gamma's products utilize proprietary "Gel Delivery Technology®," to create innovative gel product forms; that give consumers a more pleasant experience. Gel Delivery Technology® characteristics include rapid absorption, convenience and taste great. Market categories Gamma targets are growing as rapidly as 60% per year.

Gamma master brands include: Brilliant Choice®, range of children's vitamins, nutritional supplements and immune boosters, Savvy® a range of adult vitamins, nutritional supplements and immune boosters. Youth targeted products are sold as Jugular® Energy - "Go for the Jugular(TM)." In addition, Gamma has developed formulas and strategies for Metabolic Syndrome and Diabetes Type II, Stress reduction, Cognition, Well being, Menopause Symptoms, and Personal Care Products. Gamma also develops and manufactures house brands for major retailers. At this time Gamma is holding licenses for 9 SKUs in China.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact:
Gamma Pharmaceuticals Inc.
Joe Cunningham
jcunningham@gammapharma.com

Office: (702) 989 5262
Direct: (651) 204 2048


Source: Marketwire (June 23, 2009 - 8:00 AM EDT)

]]> [Press Release] Gamma Pharmaceuticals Inc. and Mr. Checkout Reach Distribution Agreement message_2415 15 Jun 2009 04:04:00 GMT http://chinasecurities.com/ir/GammaPharmaceuticals/messages/2415 LAS VEGAS, NV--(MARKET WIRE)--Jun 15, 2009 -- Gamma Pharmaceuticals Inc. (OTC BB:GMPM.OB - News) announces an agreement with Mr. Checkout, a major national network of distributors for coverage in selected territories. The initial push will be in more than 600 outlets, with an estimated retail market value of $500,000 in the first year. Gamma has established a very effective network of distributor resources and direct to retail systems throughout key markets in the USA and China. Mr. Checkout and Gamma may expand their distribution reach further, as mutually agreed, on a territory-by-territory basis.

This represents a significant push for Gamma whose brands are cited by consumers as being equal to or better than similar offerings from Pfizer Inc., Johnson & Johnson and Bayer. Gamma's CEO Peter Cunningham commented, "This is another significant piece in our distribution profile in the US market. Retail chains are very supportive of Gamma's promotional programs and have responded with immediate orders. We look forward to working with Mr. Checkout and will continue to seek distributors with consumer retail awareness and market reach."

Gamma Pharmaceuticals Inc. (www.gammapharma.com) is a marketing and product formulation company. The Company creates, registers and brands innovative product lines, including Nutritional Supplements, Personal Care Products and Over-The-Counter (OTC) pharmaceuticals. At present, Gamma manufactures in North America, and distributes in the United States and China. Gamma's products utilize a proprietary "Gel Delivery Technology®," offering one of the most innovative gel product forms; offering consumers a more pleasant experience with product forms that absorb more rapidly, are more convenient and taste great. Market categories Gamma targets are growing as rapidly as 60% per year.

Gamma master brands include: Brilliant Choice®, a range of children's vitamins, nutritional supplements and immune boosters, and Savvy®, a range of adult vitamins, nutritional supplements and immune boosters. Youth targeted products are sold as Jugular® Energy -- "Go for the Jugular"(TM); and iceDROP Instant Hand Sanitizer(TM) (Beijing); In addition, Gamma has developed formulas and strategies for Metabolic Syndrome and Diabetes Type II, Stress reduction, Cognition, Well being, Menopause Symptoms, and Personal Care Products. Gamma also develops and manufactures house brands for major retailers. At this time, Gamma holds licenses for 9 SKUs in China.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.


Contact:

     Contact:
     Gamma Pharmaceuticals Inc.
     Joe Cunningham
     jcunningham@gammapharma.com
      
     Office: 702 989 5262
     Direct: 651 204 2048
]]> [Press Release] Gamma Pharmaceuticals Inc. Expands Retail Reach in Pennsylvania message_2380 09 Jun 2009 13:07:00 GMT http://chinasecurities.com/ir/GammaPharmaceuticals/messages/2380 LAS VEGAS, NV--(MARKET WIRE)--Jun 9, 2009 -- Gamma Pharmaceuticals Inc. (OTC BB:GMPM.OB - News) announces the receipt of purchase orders from Liberty USA Inc., a major distributor in Pennsylvania, Ohio and West Virginia. The Purchase orders are for the CoGo's chain of retail outlets in the Pittsburgh area. Gamma has established a very effective network of distributor resources and direct to retail systems in its Midwest USA Territory. Gamma estimates that the brand promotion program being implemented in Pennsylvania and Ohio should lead to a retail market value for Gamma's Brilliant Choice®, SAVVY(TM) and Jugular® brands of $1,000,000 in the first 12 months, based on factors known at this time. Liberty USA Inc. covers 2,200 outlets.

This represents another significant expansion of market share for Gamma whose brands are cited by consumers as being equal to or better than similar offerings from Pfizer Inc., Johnson & Johnson and Bayer. Gamma's CEO, Peter Cunningham, commented, "We are pleased to receive this order and look forward to a very strong brand building program with CoGo's in the territory. Retail chains are very supportive of Gamma's aggressive promotion programs and are taking product immediately."

Gamma Pharmaceuticals Inc. (www.gammapharma.com) is a marketing and product formulation company. The Company creates, registers and brands innovative product lines, including Nutritional Supplements, Personal Care Products and Over-The-Counter (OTC) pharmaceuticals. At present, Gamma manufactures in North America, and distributes in the United States and China. Gamma's products utilize a proprietary "Gel Delivery Technology®," offering one of the most innovative gel product forms; offering consumers a more pleasant experience with product forms that absorb more rapidly, are more convenient and taste great. Market categories Gamma targets are growing as rapidly as 60% per year.


Gamma master brands include: Brilliant Choice®, a range of children's vitamins, nutritional supplements and immune boosters, and Savvy®, a range of adult vitamins, nutritional supplements and immune boosters. Youth targeted products are sold as Jugular® Energy - "Go for the Jugular"(TM); and iceDROP Instant Hand Sanitizer(TM) (Beijing); In addition, Gamma has developed formulas and strategies for Metabolic Syndrome and Diabetes Type II, Stress reduction, Cognition, Well being, Menopause Symptoms, and Personal Care Products. Gamma also develops and manufactures house brands for major retailers. At this time, Gamma holds licenses for 9 SKUs in China.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.


Contact:

     Contact:
     Gamma Pharmaceuticals Inc.
     Joe Cunningham
     jcunningham@gammapharma.com
     702 989 5262
     651 204 2048
]]> [Press Release] Gamma Pharmaceuticals Gets Purchase OrdersWith Market Value of Up to US $3.5m message_2366 04 Jun 2009 06:00:00 GMT http://chinasecurities.com/ir/GammaPharmaceuticals/messages/2366 LAS VEGAS, NV -- (Marketwire) -- 06/04/09 -- Gamma Pharmaceuticals Inc. (OTCBB: GMPM) has been issued Purchase Orders from market leading retail pharmacy and supermarket chains in the American Southwest. Gamma estimates the Purchase Orders should lead to incremental retail market value of $3,500,000 in the first 12 months. This is Gamma's fourth significant order in six months, demonstrating the strong momentum Gamma is gaining in the market. Peter Cunningham, Gamma's CEO, commented, "Gamma's expanding retail profile and distribution resources are significantly strengthened with the receipt of our new POs. They strengthen our existing and effective network of distributor resources and direct to retail systems in this important region, particularly in Texas." He continued, "Retail chains are very supportive of Gamma's aggressive promotional programs for the territory and are taking product immediately."

The new purchase orders represent a significant increase in Gamma's market share. Gamma's brands are cited by consumers as being equal to or better than similar offerings from Pfizer, Johnson & Johnson and Bayer Xetra, BAYG.X.

Gamma Pharmaceuticals Inc. is a marketing and product formulation company. The Company creates, registers and brands innovative product lines, including Nutritional Supplements, Personal Care Products and Over-The-Counter (OTC) pharmaceuticals. At present, Gamma manufactures in North America, and distributes in the United States and China. Gamma's products utilize a proprietary "Gel Delivery Technology®," offering one of the most innovative gel product forms; offering consumers a more pleasant experience with product forms that absorb more rapidly, are more convenient and taste great. Market categories Gamma targets are growing as rapidly as 60% per year.

Gamma master brands include: Brilliant Choice®, a range of children's vitamins, nutritional supplements and immune boosters, and Savvy®, a range of adult vitamins, nutritional supplements and immune boosters. Youth targeted products are sold as Jugular® Energy - "Go for the Jugular"(TM); and iceDROP Instant Hand Sanitizer(TM) (Beijing). In addition, Gamma has developed formulas and strategies for Metabolic Syndrome and Diabetes Type II, Stress reduction, Cognition, Well being, Menopause Symptoms, and Personal Care Products. Gamma also develops and manufactures house brands for major retailers. At this time, Gamma holds licenses for 9 SKUs in China.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact:
Gamma Pharmaceuticals Inc.
Joe Cunningham
Office: 702 989 5262
Direct: 651 204 2048


Source: Marketwire (June 4, 2009 - 8:00 AM EDT)

]]> [WebLink] OTC.BB Website weblink_184 27 Mar 2009 14:07:31 GMT http://otcbb.com/ http://otcbb.com/]]> [Photo] Gamma's GeliBitesâ„¢ MultiVitamin and Calcium photo_467 27 Mar 2009 14:06:45 GMT http://chinasecurities.com/ir/GammaPharmaceuticals/photos Gelithin_vc]]> [Photo] Gelithin Vitamin C Strip photo_466 27 Mar 2009 14:06:18 GMT http://chinasecurities.com/ir/GammaPharmaceuticals/photos Gelithin_vc]]> [Photo] CVS Airshield Chewable Immune Booster Gummy photo_465 27 Mar 2009 14:05:51 GMT http://chinasecurities.com/ir/GammaPharmaceuticals/photos Cvs_airshieldgummy]]> [Photo] Airdefenseâ„¢ Bioferrin® CrystalGel photo_464 27 Mar 2009 14:05:25 GMT http://chinasecurities.com/ir/GammaPharmaceuticals/photos Crystalgel]]> [Photo] BrilliantChoiceâ„¢ GeliBites Calciumâ„¢ photo_463 27 Mar 2009 14:04:58 GMT http://chinasecurities.com/ir/GammaPharmaceuticals/photos Calcium_gummy]]> [Photo] Airdefenseâ„¢ Immune Booster Gummy photo_462 27 Mar 2009 14:04:23 GMT http://chinasecurities.com/ir/GammaPharmaceuticals/photos Airdefense_gummy]]> [Photo] Profile photo_461 27 Mar 2009 13:59:22 GMT http://chinasecurities.com/ir/GammaPharmaceuticals/photos Gamma header]]> [Press Release] Gamma Pharma.Gets PO From Texas Distributor Worth $1,500,000 Retail Market Value message_1301 27 Mar 2009 07:00:00 GMT http://chinasecurities.com/ir/GammaPharmaceuticals/messages/1301 LAS VEGAS, NV -- (Marketwire) -- 03/27/09 -- Gamma Pharmaceuticals Inc. (OTCBB: GMPM) announces the receipt of purchase orders for its Jugular® brand Energy Products from Texas Liquid Energy Distributing Co. (TLED) of San Antonio, Texas. TLED delivers to convenience store (C-store) and supermarket chain outlets with a significant presence in the greater San Antonio market. Gamma has developed a series of dynamic marketing programs to promote its branded products. Gamma estimates the brand promotion program with TLED should lead to a retail market sale of $1,500,000 in the first 12 months.

Commenting on this important news, Gamma's CEO Peter Cunningham said, "This is another key market opportunity for our Jugular® brand. The combination of Gamma's innovative products and promotion programs, TLED's distribution resources and existing customer base support should significantly expand Gamma's revenue. C-stores get the highest daily foot traffic which is important now as the retail landscape changes. C-stores are becoming more like supermarkets, pharmacies are becoming more like C-stores and supermarkets now offer all categories of grocery, sundry and OTC pharmacy products."

Gamma Pharmaceuticals Inc. is a marketing and product formulation company. Gamma creates, registers and brands innovative product lines including Nutritional Supplements, Personal Care Products and Over-The-Counter (OTC) pharmaceuticals. At present Gamma manufactures in North America, and distributes in the United States and China. Gamma's products utilize our proprietary "Gel Delivery Technology®," offering the industry's most innovative gel product forms, providing consumers a more pleasant experience with product forms that absorb more rapidly, are more convenient and taste great. Gamma targets market categories growing as rapidly as 60% per year.

Primary Channels are retail pharmacies, supermarkets, club stores and other big box outlets, as well as the U.S. Military. Secondary channels include Internet and direct selling. Gamma uses both third party distributors and direct sales to retail.

Gamma master brands include: Brilliant Choice® range of children's vitamins, nutritional supplements and immune boosters, and Savvy® a range of adult vitamin and nutritional products. Youth targeted products are sold under the brand Jugular® Energy -- "Go for the Jugular!(TM)." In addition, Gamma sells IceDrop(TM) Instant Hand Sanitizer in China. Currently under development are formulas and strategies to address Metabolic Syndrome, Diabetes Type II, and general well-being products. Gamma also develops and manufactures house brands for major retailers. At this time, Gamma holds licenses for 9 SKUs in China.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact:

Gamma Pharmaceuticals Inc.
Joe Cunningham
651 204 2048
702 989 5262


Source: Marketwire (March 27, 2009 - 8:00 AM EDT)

]]> [Press Release] Gamma Pharmaceuticals Accepts PO Order Valued up to $850,000 message_1302 12 Mar 2009 07:01:00 GMT http://chinasecurities.com/ir/GammaPharmaceuticals/messages/1302 LAS VEGAS, March 12 /PRNewswire-FirstCall/ -- Gamma Pharmaceuticals Inc. (OTC Bulletin Board: GMPM) announces the receipt of purchase orders for its Jugular(R) brand Energy Products from Folsom Distributing in St. Louis, Missouri. Folsom Distributing services the QuikTrip Convenience Store outlets in St. Louis and the surrounding area. QuikTrip requested Folsom Distributing to contract directly with Gamma on its behalf. Gamma has developed a series of programs to promote its branded products. Gamma estimates that its brand promotion program developed for the St. Louis Market should result in revenue of up to $850,000 in the territory over the next 12 months. Gamma's CEO Peter Cunningham commented, 'Our QuikTrip relationship will significantly boost Gamma's Jugular(R) branded products in this important market. We feel QuikTrip, the premier convenience store chain in St. Louis, will drive our market share performance and overall brand profile.'

Gamma Pharmaceuticals Inc. is a marketing and product formulation company. Gamma has created, registered and branded innovative product lines that include Nutritional Supplements, Personal Care Products and Over-The-Counter (OTC) pharmaceuticals. At present, Gamma manufactures in North America, and distributes in the United States and China. Gamma's products utilize its patent pending 'Gel Delivery Technology(R)'; offering consumers one of the most innovative gel product lines in the market today. Gamma uses its patent pending gel delivery technology to formulate one of the industry's only full suites of gel based products. Gamma benefits from a clear consumer preference for gel product forms; offering consumers a more pleasant experience with product forms that absorb more rapidly, are more convenient and taste great. Market categories Gamma targets are growing as rapidly as 60% per year. Gamma targets consumers in the fast growing Greater China and U.S. wellness and healthcare markets. Primary channels are retail pharmacies, supermarkets, club stores and other big box outlets. Secondary channels include internet and direct selling. Gamma uses third party distributors and sells directly to retail outlets.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

SOURCE Gamma Pharmaceuticals Inc.


Source: PR Newswire (March 12, 2009 - 8:01 AM EDT)

]]> [Broadcast] Welcome to Chinasecurities broadcast_219 27 Mar 2009 14:08:39 GMT http://chinasecurities.com/ir/GammaPharmaceuticals/webcasts/219 [Press Release] Gamma Pharmaceuticals Accepts Purchase Orders From the Largest Convenience Store message_1303 18 Dec 2008 09:34:00 GMT http://chinasecurities.com/ir/GammaPharmaceuticals/messages/1303 LAS VEGAS, Dec. 18 /PRNewswire-FirstCall/ -- Gamma Pharmaceuticals Inc. (OTC Bulletin Board: GMPM) announces the receipt of purchase orders for its Jugular(R) brand Energy Products. Terrible Herbst convenience store chain is featuring Gamma's Jugular(R) brand Energy Products and the always exciting Jugular(R) brand promotion programs. To service Terrible Herbst outlets, Gamma teamed up with International Wholesale Supply, Inc. Gamma estimates that the brand promotion program being implemented with Terrible Herbst should lead to their achieving up to $2.0 million revenue in the next 12 months, contributing to a significant market share for the Jugular(R) brand in the important Nevada market.

Gamma's CEO Peter Cunningham commented, 'The combination of Gamma's innovative product range and promotion programs with distribution by International Wholesale Supply, Inc and retail support by and retail presence, Terrible Herbst should significantly expand Gamma's revenues. All three companies are strong, innovative and quick to seize opportunities.' Mr. Cunningham went on to say, 'For Jugular(R) brand, our key measure is market share, and Terrible Herbst is the C-store trend setter nationwide. C-stores get the highest daily foot traffic which is important now as the retail landscape changes. C-stores are becoming more like supermarkets, pharmacies are becoming more like C-stores and supermarkets now offer all categories of grocery, sundry and pharmacy products. With the Terrible Herbst experience, Gamma is positioned to take advantage of the change in the retail channels nationwide.'

Gamma Pharmaceuticals Inc. (www.gammapharma.com) is a marketing and product formulation company. We have created, registered and branded innovative product lines including Nutritional Supplements, Personal Care Products and Over-The-Counter (OTC) pharmaceuticals. At present, Gamma manufactures in North America, and distributes in the United States and China. Gamma's products utilize our proprietary 'Gel Delivery Technology' (Gel Delivery Technology Gamma(R)). Gamma offers consumers one of the industry's only full suite of gel product forms, including solid gels, liquid gels, crystal gels and gel strips. Gamma's leading position in gel technologies enables the Company to profit from consumer preferences which are moving away from pills and capsules and towards new and more effective gel product forms. Gamma presents consumers with a choice that offers a more pleasant experience with convenient, great tasting and fast acting product forms. Gamma has formulated products for market categories that are growing at as much as 60% per year. Gamma targets consumers in the fast growing Greater China and U.S. wellness and healthcare markets (LOHAS) and the youth energy products market with Gel products. Gamma uses third party distributors or sells direct to retail.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur. 

    Contact:

    Gamma Pharmaceuticals Inc.

    Joe Cunningham

    702 989 5262
    651 204 2048
    www.gammapharma.com
    jcunningham@gammapharma.com

SOURCE Gamma Pharmaceuticals Inc.


Source: PR Newswire (December 18, 2008 - 10:34 AM EST)

]]>